In the recent years, targeting the uroguanylin-GUCY2C endocrine axis using peptides (36) or drugs (26) has been proposed as a therapeutic strategy for the treatment of obesity (18). The gene discussed is GUCA2B; the disease is obesity due to melanocortin 4 receptor deficiency.